DYN Drops on DMD Endpoint Change — Opportunity or Warning?

Another interesting company to diligence is Dyne Therapeutics (DYN). Their shares were hit pretty hard this week, apparently because they changed primary outcomes for their upcoming DMD readout. Did the market over-react to that, and in the wrong direction? That is something to dig deeper into.

In the meantime, DYN is in all of our portfolios except the Run-Up, but we plan to initiate a position in DYN in the run-up by the end of the month ahead of its readout by end of the year for its other asset, 251. We also just marked this readout as a suspected Big Mover. #DYN

---

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 6/20/25 EJV & AV